Management of Placenta Accreta Spectrum

Placenta Accreta Clinical Trial

Official title:

Management of Placenta Accreta Spectrum

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04609527
• Other study ID #: Placenta Accreta
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: October 16, 2020
• Est. completion date: December 31, 2021

Study information

• Verified date: October 2020
• Source: Assiut University
• Contact: Osama Abdalmageed
• Phone: 01012234876
• Email: drosamast[@]aun.edu.eg
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

placenta accreta spectrum is group of disorders which have a depate about the best way of management. this is a descriptive study about the best techniques to reduce morbidity and mortalities related to it.

Description:

placenta accreta spectrum is group of disorders which have a depate about the best way of management. this is a descriptive study about the best techniques to reduce morbidity and mortalities related to it. 1. surgical management of placenta accreta 2. short term follow up to the outcomes 3. long term follow up

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• All placenta accreta e high possibility of placenta accrete
• consent
• easy follow up visits

Exclusion Criteria:

• bleeding tendency
• associated medical disorder hypertension, diabetes, preeclapsia..

Related Conditions & MeSH terms

• Placenta Accreta
• Placenta Previa

Intervention

Procedure:
• Management of placenta accreta spectrum
Conservative and radical (hysterectomy) treatment of placenta accreta. Follow up to the patients to detect the impact of treatment imposed A novel technique which early identification and repait of uterine wall defects resulted from invasion of the uterine wall by the placenta.

Locations

Country	Name	City	State
Egypt	Assiut University	Assiut
Egypt	Osama Abdalmageed	Assiut	Non-US/Non-Canadian

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Failure of the novel conservative management	Need to do peripartum hysterectomy or patient death	3 hours
Primary	Estimated amount of blood loss	The estimated amount of blood loss during and after surgery	6 hours